The latest update is out from OncoCyte ( (OCX) ).
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Oncocyte Corporation has announced a private sale of over 3.4 million shares at $2.948 each to accredited investors, with the expected closing date around October 4, 2024. The deal includes typical closing conditions, indemnifications, and a registration rights agreement to file with the SEC for the resale of shares. The company anticipates raising approximately $10.2 million before fees and expenses, which will be used for general corporate needs and working capital. The private sale was facilitated by Needham & Company, LLC as the exclusive placement agent.
For an in-depth examination of OCX stock, go to TipRanks’ Stock Analysis page.
